Program
ecnoglutide
Also written as “XW003 injection”, “ecnoglutide tablets” and “Ecnoglutide Injection”.
Its studies are mostly in Obesity · Sleep Apnea, Obstructive · Diabetes Mellitus, Type 2 · Osteoarthritis, Knee, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Sciwind Biosciences | 127 open or running | phase 3since Dec 25, 2022 | Dec 25, 2022 | Jan 5, 2027phase 2 · NCT07243171 |
| Sciwind Biosciences APAC CO Pty. | 10 open or running | phase 2since Oct 17, 2021 | Oct 17, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2021First study: phase 2 study in ObesityNew to Sciwind Biosciences APAC CO Pty.Sciwind Biosciences APAC CO Pty. · NCT05111912 · 206 enrolled · Australia
- Dec 25, 2022Hangzhou Sciwind Biosciences's first studies: 2 phase 3 studies in Diabetes Mellitus, Type 2New to Hangzhou Sciwind BiosciencesHangzhou Sciwind Biosciences · NCT05680155, NCT05680129
- Mar 20, 2023Phase 3 study in OverweightHangzhou Sciwind Biosciences · NCT05813795 · 664 enrolled · China
- Jul 29, 2023Phase 1 study in Healthy VolunteersHangzhou Sciwind Biosciences · NCT06335134 · 57 enrolled · China
- Jul 9, 2025Phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07073417 · 163 enrolled · China
- Aug 13, 2025Phase 1 study in ObesityHangzhou Sciwind Biosciences · NCT07143227 · 48 enrolled · China
- Nov 17, 2025Phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07243171 · 126 planned · China
- Jan 28, 20262 phase 3 studies in Sleep Apnea, ObstructiveHangzhou Sciwind Biosciences · NCT07434050, NCT07387094
- Jul 21, 2026Phase 3 study in Osteoarthritis, KneeHangzhou Sciwind Biosciences · NCT07734311 · 360 planned · China
- Sep 14, 2026Phase 3 study in ObesityHangzhou Sciwind Biosciences · NCT07836270 · 192 planned · China
- Oct 28, 2026Phase 2 study in OverweightHangzhou Sciwind Biosciences · NCT07929298 · 180 planned · China
Ahead
- Jan 5, 2027Primary completion: phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07243171
- Feb 27, 2027Primary completion: phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07073417
- Sep 3, 2027Primary completion: phase 2 study in OverweightHangzhou Sciwind Biosciences · NCT07929298
- Dec 16, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveHangzhou Sciwind Biosciences · NCT07387094
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07929298Overweight · China | 2 | Not yet recruiting | Hangzhou Sciwind Biosciences | Sep 3, 2027 | 180 |
| NCT07836270Obesity · China | 3 | Not yet recruiting | Hangzhou Sciwind Biosciences | Jun 8, 2028 | 192 |
| NCT07734311Osteoarthritis, Knee · China | 3 | Recruiting | Hangzhou Sciwind Biosciences | May 31, 2028 | 360 |
| NCT07434050Sleep Apnea, Obstructive · China | 3 | Recruiting | Hangzhou Sciwind Biosciences | Jun 19, 2028 | 140 |
| NCT07387094Sleep Apnea, Obstructive · China | 3 | Recruiting | Hangzhou Sciwind Biosciences | Dec 16, 2027 | 140 |
| NCT07243171Obesity · China | 2 | Recruiting | Hangzhou Sciwind Biosciences | Jan 5, 2027 | 126 |
| NCT07143227Obesity · China | 1 | Completed | Hangzhou Sciwind Biosciences | Apr 18, 2026 | 48 |
| NCT07073417Obesity · China | 2 | Active, not recruiting | Hangzhou Sciwind Biosciences | Feb 27, 2027 | 163 |
| NCT06335134Healthy Volunteers · China | 1 | Completed | Hangzhou Sciwind Biosciences | Jan 8, 2024 | 57 |
| NCT05813795Overweight · China | 3 | Completed | Hangzhou Sciwind Biosciences | Jun 20, 2024 | 664 |
| NCT05680155Diabetes Mellitus, Type 2 · China | 3 | Completed | Hangzhou Sciwind Biosciences | Jun 12, 2024 | 211 |
| NCT05680129Diabetes Mellitus, Type 2 · China | 3 | Completed | Hangzhou Sciwind Biosciences | Jul 3, 2024 | 623 |
| NCT05111912Obesity · Australia | 2 | Completed | Sciwind Biosciences APAC CO Pty. | Nov 16, 2022 | 206 |
How it is read
Names in the registry
- “XW003 injection”, 5 entries
- “ecnoglutide tablets”, 2 entries
- “Ecnoglutide Injection”, 2 entries
- “ecnoglutide tablet”, 1 entry
- “Ecnoglutide”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Sleep Apnea, Obstructive, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.